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Abstract
Collaboration of T helper (T
h
) cells with B cells is central for the generation of high-affin-
ity antibodies with distinct effector function and thus for the establishment of effective 
immune responses. Physiological T cell help for B cells takes place in germinal centers (GC) 
in peripheral lymphoid organs, where follicular T helper (Tfh) cells interact with mature, antigen-stimulated B cells. Occasionally, B cells undergo malignant transformation, which 
may lead to the development of leukemia or lymphoma. Over the past decades, it has 
become increasingly clear that cancer cells depend on interactions with the tumor micro-
environment for growth and survival. Since many B cell malignancies develop in GC—the 
place of physiological T
h
 cell-B cell interaction—T
h
 cells are a central part of the tumor 
microenvironment of B cell leukemia and lymphoma. Thus, while the interaction between 
T
h
 cells and normal B cells is crucial for the development of an effective immune response, 
this interaction also contributes to the development and pathogenesis of malignancies. The 
present chapter discusses the mechanisms underlying T
h
 cell-mediated support of malig-
nant B cells contributing to the pathogenesis of leukemia and lymphoma. Research efforts 
aiming to elucidate such mechanisms are of high importance as therapeutic targeting of 
these malignant interactions may increase treatment efficiency and reduce disease relapse.
Keywords: T helper cells, B cells, leukemia, lymphoma, B cell malignancies, T
h
 cell-B cell 
interaction, tumor microenvironment
1. Introduction
The human immune system is made up of two branches: the innate immune system consisting 
of dendritic cells, macrophages, granulocytes and natural killer (NK) cells mounts a fast but 
nonspecific response against invading pathogens. The adaptive immune system, in contrast, 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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raises a delayed but highly specific response. In this response, T cells and B cells use their 
greatly diverse receptors—T cell receptors (TCRs) and B cell receptors (BCRs), respectively—to 
recognize antigenic epitopes of invading pathogens [1]. Antigenic stimulation of the recep-
tors on the B cell’s and T cell’s surface induces intracellular signaling cascades that lead to 
the activation, proliferation and differentiation of the cell. The BCR is also synthesized in a 
soluble form and can be secreted by B cells as antibody, also known as immunoglobulin (Ig). 
Antibodies recognize pathogens and neutralize them by various mechanisms. In order to gen-
erate high-affinity antibodies with distinct effector functions, B cells need the help of T cells. 
Thus, the establishment of a specific and efficient immune response requires a close collabora-
tion of T cells and B cells.
1.1. Physiological T
h
 cell-B cell interaction
T cells arise in the bone marrow (BM) and mature in the thymus. Two T cell populations can 
be distinguished: the CD8+ T cytotoxic (T
c
) cells and the CD4+ T
h
 cells. T
c
 cells can kill infected 
cells through release of molecules like granzymes or perforin, while T
h
 cells have the task to 
activate other immune cells and to instruct them to raise an appropriate immune response.
Naïve T
h
 cells leave the thymus and migrate to the periphery, where they encounter antigenic 
peptides presented by antigen-presenting cells (APCs) such as macrophages, B cells and den-
dritic cells (DCs). APC secrete a distinct set of cytokines, the composition of which depends 
on the pathogen encountered. Upon stimulation, the activated T
h
 cells rapidly divide and 
differentiate into one of several different effector subsets that are characterized by the expres-
sion of distinct transcription factors, surface markers and cytokines. This differentiation is 
governed by the cytokines that are secreted by the APC and the surrounding cells at the time 
point of naïve T
h
 cell activation. Thereby, APC not only activates naïve T
h
 cells but also tailors 
their properties according to the pathogens to be defeated.
The first T
h
 cell subsets that have been described were T
h
1 cells, characterized by expression 
interferon (IFN)-γ, and T
h
2 cells, producing interleukin (IL)-4, IL-5 and IL-13 [2]. Later, further 
effector lineages such as T
h
17, T
h
9 or T
h
22 have been described. In addition, several T
h
 cell 
subsets with regulatory or suppressive functions, so-called regulatory T (T
reg
) cells, exist [3].
Follicular helper T (Tfh) cells are a unique population of Th cells distinct from extrafollicular 
and peripheral T
h
 cells. Tfh cells are characterized by the expression of the inducible T cell costimulator (ICOS) receptor, the chemokine receptor CXCR5, the programmed cell death-1 
(PD-1) inhibitory receptor and the transcription factor BCL6 that controls their development 
and function [4–6].
B cells develop and mature in the BM and then migrate to the secondary lymphoid organs, 
where the antigen-dependent phase of their development takes place. While this process can 
be independent of T cell help, conventional B cells predominantly undergo T cell-dependent 
(TD) responses. Upon BCR stimulation by an antigen presented by follicular dendritic cells 
(FDCs), B cells migrate to the boundary between the follicle and the outer T cell zone, where 
they interact with Tfh cells [7]. Cognate interaction of B cells and Tfh cells involves internaliza-tion and presentation of an antigen via the BCR, ligation of CD40 on the B cell by its ligand 
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CD40L on the Tfh cell, as well as the cytokines IL-4 and IL-21. B cells then develop either into short-lived plasma cells that secrete low-affinity antibodies or they differentiate into GC B 
cells that further give rise to long-lived memory B cells and plasma cells producing high-
affinity antibodies. While memory B cells enter the circulation, plasma cells migrate and home 
to the BM.
The activating signals from Tfh cells induce upregulation of activation-induced cytidine deami-nase (AID), a DNA-editing enzyme that initiates somatic hypermutation (SHM) and class-
switch recombination (CSR) [8]. Introduction of point mutation by AID into the variable region 
of the IG genes during SHM leads to highly variable Ig proteins that build the base for high-
affinity antibodies [9]. During CSR, the constant parts of IgM and IgD (C
μ
 and Cδ, respectively) 
are replaced by Cγ, Cα or Cε, giving rise to IgG, IgA or IgE. Thereby, CSR creates antibodies with diverse effector functions while retaining the antigen specificity [10]. B cells then differen-
tiate into highly proliferating GC B cells called centroblasts before developing into centrocytes. 
As centrocytes, they screen antigens on the surface of FDC using their newly mutated BCR. 
High-affinity interaction with antigen results in survival and thus selection of centrocytes with 
high-affinity BCR, leading to recycling of centrocytes into centroblasts and to the differentia-
tion of centrocytes into memory B cells and plasma cells.
During B cell development, however, B cells or their precursors occasionally undergo malignant 
transformation, which may result in the development of leukemia or lymphoma (Figure 1). 
Such transformations are frequently initiated by genetic events leading to aberrantly expressed 
proteins. Nevertheless, these chromosomal abnormalities alone are usually not sufficient for 
Figure 1. Schematic overview over the B cell development in the BM and GC with the most important developmental 
stages (black) and the B cell malignancies covered in this chapter (red). Red arrows indicate the presumed cell of origin 
of the malignant cells.
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cancer development, and the transformed cells are not able to survive and outgrow when 
isolated and cultured in vitro. Thus, while mutations may trigger malignant transformation, 
interactions with the tumor microenvironment seem to be essential for the development and 
pathogenesis of most B cell malignancies.
2. Main body
2.1. Malignant T
h
 cell-B cell interaction
The tumor microenvironment plays a key role in supporting survival and expansion of cancer 
cells in virtually all known malignancies [11–13]. Malignancies of B cell origin often arise from GC 
B cells. Consequently, the cells of the GC microenvironment represent key collaboration partners 
of cancer cells during pathogenesis, progression and relapse of leukemia and lymphoma. The 
supportive tumor microenvironment in GC is made up by nonhematopoetic as well as lymphoid 
cells such as mesenchymal stromal cells, fibroblasts, macrophages, FDC and Tfh cells, which build a complex network and mutually regulate their activation differentiation, migration and expan-
sion. Thus, while cells of the microenvironment support the tumor cells, the tumor cells in turn 
support and shape the cells that surround them in a way that maximizes their own benefit.
Generally, malignantly transformed B cells seem to retain their ability to interact with T
h
 cells, 
and thus remain capable of profiting from T
h
 cell help. Hence, while the support of normal 
mature B cells by T
h
 cells plays a central role in the generation of an adaptive immune response, 
the support of malignant B cells by T
h
 cells may promote lymphoma or leukemia.
2.2. Malignant T
h
 cell-B cell interaction: follicular lymphoma
Follicular lymphoma (FL) is the most frequent indolent lymphoma. The initial response rates 
to therapy are relatively high but relapses are frequent. The malignant cells express the GC 
B cell markers BCL6 and CD10 and display a gene expression profile of centrocytes [14]. 
FL cells are characterized by an overexpression of the antiapoptotic protein BCL2 caused by 
a t(14;18) translocation. Nevertheless, this genetic aberration is not sufficient for lymphoma 
development, and isolated primary FL cells fail to survive and proliferate in vitro, suggesting 
that the tumor microenvironment plays a major role in FL development and progression. 
Both nonhematopoietic cells as well as T
h
 cells are crucially involved in FL cell growth and 
survival [15]. Tfh cells from FL-affected lymph nodes display a distinct gene expression pro-file that differs from normal tonsillar Tfh cells by an increased expression of IL2, IL4 and the proinflammatory cytokines IFN and TNF [16]. Consistently, high levels of IL-4 are associated 
with FL cell activation [17]. Similarly, support of FL cells by T
h
 cells seems to be mediated by 
Tfh cell-derived CD40L and IL-4 [18]. The proinflammatory cytokines expressed by Tfh of FL patients, in contrast, seem to modulate the FL supportive environment rather than having a 
direct effect on FL cells. TNF, e.g., has been suggested to sustain differentiation and survival 
of the lymphoid stroma network in FL [19].
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Besides cytokines, the membrane-bound molecule CD40L is important for T
h
 cell-mediated 
FL cell support, since FL cells showed an increased survival when stimulated by CD40 cross-
linking in vitro [20] as well as upon cognate interaction with T
h
 cells [21], and it has been 
suggested that CD40L stimulation protects FL cells from TRAIL-mediated apoptosis in an 
NF-κB-dependent manner [22].
About 70% of FL patients display BM infiltration at diagnosis. Interestingly, the affected BM 
is characterized by an overrepresentation of T
h
 cells [23]. This further supports the importance 
of Tfh cells in FL disease pathogenesis.
2.3. Malignant T
h
 cell-B cell interaction: Burkitt’s lymphoma
Burkitt’s lymphoma (BL) is an aggressive B cell cancer, probably arising from GC B cells 
[24]. Three main subtypes of BL are currently identified epidemiologically, though histo-
logically the tumors are indistinguishable. Endemic BL (eBL), the classical BL, is found in 
malaria-endemic regions, while sporadic BL (sBL) is relatively rare and most commonly 
found outside malaria-affected areas. HIV-associated BL is often described as separate 
subtype as well [25]. eBL is strongly associated with the Epstein-Barr Virus (EBV), even 
though the pathogenic mechanism is not clear [26, 27]. The role of T
h
 cells in BL develop-
ment and progression is highly controversial. Several studies showed that EBV-specific T
h
 
cells can kill BL cell lines or EBV-transformed B cells [28–35] or limit their proliferation [36]. 
Most of these studies, however, used a nonphysiologically high effector to target ratio and 
thus require careful interpretation. Other researchers, in contrast, have reported that EBV-
specific T
h
 cells induced B cell proliferation [37], and in several mouse models EBV-specific 
T
h
 cells were even required for lymphomagenesis [38–40]. Finally, two studies found that 
virus and autoantigen-specific T
h
 cells can both kill and support EBV-transformed B cells 
[41, 42], suggesting that the role of T
h
 cells in BL and other EBV-associated malignan-
cies is likely to be context dependent. Interestingly, the chance of BL development in HIV 
patients is associated with CD4+ T cell count, as the incident of BL development decreases 
with reduced CD4+ T cell numbers [43], supporting a BL-promoting role for T
h
 cells.
2.4. Malignant T
h
 cell-B cell interaction: Hodgkin lymphoma
In Hodgkin lymphoma (HL), the malignant B cells—called Reed-Sternberg (RS) cells—con-
stitute only a minor fraction of the tumor. The remainder consists of eosinophils, fibroblasts, 
macrophages, plasma cells and T
c
 as well as T
h
 cells. Infiltration of certain T
h
 cell subsets has 
been correlated with reduced overall patient survival, even though the exact function of these 
infiltrating T
h
 cells is not fully clear [44, 45]. Several cytokines seem to have a stimulatory effect 
on RS cells, one of which is the T
h
2 cytokine IL-13 [46]. Nevertheless, IL-13 can also be produced 
by RS cells themselves and act in an autocrine manner. Thus, a direct role of T
h
 cells remains to 
be demonstrated. The complexity of the tumor microenvironment in HL, where a wide range 
of cells mutually influence each other, makes it intricate to discern the roles of the individual 
components.
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2.5. Malignant T
h
 cell-B cell interaction: chronic lymphocytic leukemia
Chronic lymphocytic leukemia (CLL) is a malignancy of mature clonal CD5+ B cells, although 
the precise cell of origin is still debated [47]. CLL cells proliferate in pseudofollicles in second-
ary lymphoid organs and in the BM, where they receive support from cells of the stromal 
microenvironment [48]. CLL cells were found to interact with endothelial cells, stroma cells 
and monocyte-derived nurse-like cells, and to receive antiapoptotic signals via cytokines and 
chemokines. In addition, T
h
 cells infiltrate such CLL pseudofollicles [49]. The infiltrating T
h
 
cells were shown to have an activated phenotype and to be actively recruited to these niches by 
CLL cells via chemokines [50]. Furthermore, they were able to activate CLL cells and to induce 
an upregulation of the surface molecule CD38, which is associated with poor prognosis [51].
We hypothesized that proliferation of CLL cells in patients was driven by a cognate interac-
tion of T
h
 cells with CLL cells, comparable to the physiological interaction between T
h
 cells 
and GC B cells [52]. According to this hypothesis, CLL cells would present antigen to antigen-
specific T
h
 cells and in turn receive stimuli for their survival. Such an antigen could either be 
endogenous or it could be derived from an external pathogen. A key premise for this mecha-
nism of CLL expansion in patients is the ability of resting CLL cells to efficiently activate T
h
 
cells. Thus, to study the antigen-presentation capacity of CLL cells, we used a human T
h
 cell 
clone that is specific for a peptide derived from the mouse Ig kappa (Igκ) light chain [53], and 
human leukocyte antigen (HLA)-matched CLL cells from CLL patients, which allowed us to 
study antigen-dependent cognate interaction of CLL cells and T
h
 cells (Figure 2). Using this 
model, we found that CLL cells were able to endocytose antigen through endocytic receptors 
such as the Fc receptors CD32 and CD23 and through their BCR. Furthermore, CLL cells were 
surprisingly potent stimulators of T
h
 cell proliferation. With the exception of one patient, the 
Figure 2. Model system to assess the antigen-presentation capacity of CLL cells: HLA-DRB1*0401+ CLL cells are 
cocultured with a human T
h
 cell clone (T18) that is specific for an epitope in mouse Igκ chain, when presented on HLA-
DRB1*0401. Mouse Igκ+ antibodies against various surface molecules on the CLL cells such as CD23, CD32 or BCR are 
added. T18 cell proliferation is assessed as a read out for the capacity of CLL cells to endocytose and process these 
antibodies and to present Igκ peptides to the T18 cells together with provision of costimulatory signals.
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function of CLL cells was comparable to that of normal B cells. Reciprocally, CLL cells were 
activated by antigen-activated T
h
 cells. They upregulated the activation markers CD38 and 
CD69, and molecules involved in the interaction with T
h
 cells such as HLA-DR, the costimu-
latory molecule CD86, the adhesion molecule CD54 and receptors for T
h
 cell help such as 
CD40 and CD25. Surface expression of CD27 and CD275 (ICOS-ligand) was reduced, in line 
with activation-induced shedding. In addition, CLL cells proliferated upon interaction with 
T
h
 cells, which was dependent on antigen and cell-cell contacts, as well as on CD40-CD40L 
interaction. Furthermore, the T
h
 cell-stimulated CLL cells had a gene expression profile simi-
lar to CLL cells within CLL proliferation centers, suggesting that in vitro interactions with T
h
 
cells reflected interactions with the lymph node microenvironment in patients.
While the results obtained using this model system demonstrated that CLL cells had the abil-
ity to activate T
h
 cells and receive help for their survival and proliferation, it remained to be 
elucidated whether such interaction actually occurred in CLL patients. Indeed, we found that 
CLL patients harbored T
h
 cells that proliferated in response to both autologous CLL cells as 
well as autologous CLL cell lysate presented by peripheral blood mononuclear cells (PBMCs) 
from HLA-matched donors. Similar to the results obtained using the model system, CLL-
specific T
h
 cells stimulated CLL cell activation and proliferation in an antigen- and CD40L-
dependent manner. In in vivo xenograft experiments, the T
h
 cell-induced CLL proliferation 
was even more pronounced, suggesting that stromal factors may act synergistically during 
the T
h
 cell-CLL cell collaboration.
The remaining unresolved point was the identification of the antigenic source of the cognate 
interaction between T
h
 cells and CLL cells. The hypervariable regions of the CLL cells’ BCR 
represent good candidate for endogenous antigens, since peptides derived from these regions 
are presented on major histocompatibility complex class II (MHCII), and are likely to be rec-
ognized as foreign by autologous T
h
 cells.
To test this hypothesis, we used monoclonal antibodies derived from CLL cell hybridoma as 
source of antigen and HLA-matched donor PBMC as antigen-presenting cells, and assessed 
proliferation of autologous T
h
 cells. Indeed, a significant fraction of T
h
 cells proliferated upon 
stimulation with CLL-BCR-derived antigen, demonstrating that effector T
h
 cells specific for 
endogenous CLL antigens are present in CLL patients and that they can support CLL cell 
activation and expansion.
Interestingly, the patient-derived CLL-specific T
h
 cells had a T
h
1-like phenotype, characterized 
by IFN-γ secretion as well as expression of the IFN-γ-associated transcription factor T-bet and 
the surface markers CXCR3 and CCR5. In contrast, they lacked typical Tfh markers such as CXCR5, ICOS, PD-1, or IL-21 and BCL-6. These findings are in agreement with the observation 
that IFN-γ levels in CLL patients as well as IFN-γR expression on CLL cells correlated with 
disease severity [54–56]. Even though the exact mechanisms remain to be elucidated, IFN-γ 
seems to confer resistance to apoptosis and to increase CLL migration. We further demon-
strated that IFN-γ secretion was a major mechanism by which CLL-specific T
h
 cells increased 
CD38 expression on CLL cells [57]. CD38 levels on CLL cells are an indicator of poor progno-
sis, even though a mechanistic involvement of CD38 in CLL pathogenesis is still debated [58]. 
Within a patient, proliferating CLL cells are more frequently found in the population that 
Malignant Interaction between B Cells and T Helper Cells
http://dx.doi.org/10.5772/intechopen.68731
85
has a higher CD38 expression, and CD38 has been linked to CLL cell migration and survival. 
In our studies, we found that expression of the IFN-γ-inducible transcription factor T-bet in 
peripheral blood CLL cells is significantly correlated with CD38 expression [57]. Furthermore, 
T
h
 cell-derived IFN-γ upregulated CD38 in a mechanism that involved binding of the tran-
scription factor T-bet to two consensus sites in 5′-regulatory regions of intron 1 of the CD38 
gene. Thus, it seems that T
h
 cell promote the development of a more aggressive CLL subset 
through secretion of IFN-γ.
CLL cells seem to express polyreactive and/or autoreactive BCR that provide a certain level of 
constant signaling [59, 60]. However, sustained BCR signaling can induce anergy and apop-
tosis. Our studies are in agreement with the view that CLL cells are autoreactive B cells that 
are rescued from anergy by combined BCR and CD40L activation [50–52, 57, 61, 62]. BCR 
signaling components such as the kinase Syk are promising drug targets in CLL [63–65]. 
Thus, we studied how BCR pathway inhibitors may impact the T
h
 cell help of CLL cells [66]. 
Interestingly, we found that stimulation by CD40L activated the BCR pathway in CLL cells, 
including Syk and the downstream components Akt, BLNK, Btk/Itk and pErk1/2. This acti-
vation—indicated by blastogenesis and proliferation—was significantly higher in CLL cells 
compared to normal B cells and could be blocked by Syk inhibition in CLL cells but not in 
normal B cells.
2.6. Malignant T
h
 cell-B cell interaction: multiple myeloma
Multiple myeloma (MM) is a malignancy characterized by the expansion of plasma cell-
derived myeloma cells in the BM. The BM of MM patients and patients with monoclonal 
gammopathy of undetermined significance (MGUS) display increased numbers of T cells [67], 
but their role in MM disease development is not fully understood. Primary human MM cells 
express MHCII molecules as well as the costimulatory molecules CD80 and CD86 and have 
been shown to be good antigen-presenting cells for T
h
 cells [68, 69]. In addition to the fact that 
they express high levels of CD40, this suggests that they can participate in cognate interac-
tions with T
h
 cells and benefit from their support. Indeed, CD40 stimulation induced MM 
cell migration, which is associated with MM disease progression [70]. CD40 stimulation also 
triggered secretion of IL-6 by myeloma cells, which may mediate MM cell proliferation in 
an autocrine and/or paracrine mechanism [71]. In addition to CD40L-mediated stimulation, 
myeloma-specific T
h
 cells can also support MM cells by secreting cytokines [72]. T
h
17 cyto-
kines such as IL-17 enhanced proliferation of MM cell lines in vitro and in vivo, and supported 
colony formation of primary human MM cells.
Very recently, we demonstrated that polyclonally activated allogeneic as well as autologous 
T
h
 cells stimulated blastogenesis and proliferation of MM cells in a CD40L-dependent manner 
[73]. MM cells increased their cell size, became more granular, reduced their cell surface Ig 
expression and upregulated the expression of HLA-DR. Proliferation of MM cells was even 
more pronounced when the T
h
 cell growth factors IL-2 and IL-15 were added. The T
h
 cells from 
MM patients expressed the chemokine receptors CXCR3 and CCR6 and the transcription fac-
tor T-bet as well as low levels of ROR-γt, thus displayed a T
h
1/17 phenotype. Compared to T
h
 
cells from healthy controls, the MM patient-derived T
h
 cells produced lower amounts of IL-4, 
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IL-10, IL-13, and IFN-γ and TNF-α, but higher levels of IL-1β, IL-2, IL-6 and IL-17. Together, 
our recent study and the previous reports by others suggest that CD40L stimulations is a key 
mechanism in T
h
 cell-mediated MM cell support, but cytokines such as IL-6 and IL-17 are 
important components as well.
2.7. Malignant T
h
 cell-B cell interaction: precursor B cell acute lymphoblastic leukemia
The B cell malignancies described in this chapter so far all originate from mature B cells. In 
contrast, precursor B acute lymphoblastic leukemia (BCP-ALL) derives from B cells of precur-
sor stages during B cell development in the BM. As in most malignancies, the tumor micro-
environment plays a key role in BCP-ALL development and progression [12]. Mesenchymal 
stromal cells, BM endothelial cells, osteoblasts as well as adipocytes have been described to 
support survival and proliferation of BCP-ALL cells and to confer drug resistance in mecha-
nisms involving both soluble factors and cell membrane-bound molecules.
Memory T
h
 cells generated in the periphery during an immune response migrate to the BM in 
order to provide long-term memory [74–77]. These BM T
h
 cells seem to play a crucial role in 
normal hematopoiesis [78], but the knowledge about the physiological interactions between 
BM T
h
 cells and normal precursor B cells is very limited. Both normal precursor B cells and 
BCP-ALL cells express CD40 [79], MHCII, molecules for adhesion and costimulation [80], 
receptors for cytokines such as IL-2 and IL-6 [81–85] and receptors for BAFF [86, 87]. Thus, 
they possess all molecules required for cognate interaction with T
h
 cells and therefore seem 
to be capable of receiving support through the conventional T
h
 cell-B cells interaction path-
ways. BCP-ALL cells are indeed able to respond to CD40L stimulation with proliferation [88] 
and with upregulation of the surface molecule CD70 [89]. Furthermore, they upregulate the 
receptor for IL-3 [90], a cytokine that induces BCP-ALL cell proliferation. Stimulation with 
CD40L also induces the secretion of chemoattractants [91] and upregulates components of the 
antigen-processing machinery [92], suggesting that BCP-ALL cells are able to attract T
h
 cells 
and activate them, thereby inducing a positive feedback loop. T
h
 cell-derived cytokines can 
act on BCP-ALL cells as well, albeit with diverse effects. IL-2, IL-17 and IL-21, e.g., have been 
found to stimulate proliferation [83, 93], while IL-4 and IL-13 inhibited BCP-ALL cell growth 
[88, 94–96], and IL-4 as well as TGF-β-induced apoptosis [97, 98]. Cell-cell contact of BCP-ALL 
cells and activated allogenic T
h
 cells induced activation and maturation of BCP-ALL cells [99]. 
Further support of an involvement of T
h
 cell in BCP-ALL development comes from the obser-
vation that BCP-ALL is associated with certain MHCII haplotypes, suggesting that antigen-
presentation to T
h
 cells is involved in the pathogenic mechanisms contributing to BCP-ALL 
development [100, 101]. In summary, there is evidence that BCP-ALL possess the capacity to 
exploit microenvironmental T
h
 cells, but whether such leukemia supportive T
h
 cell-BCP-ALL 
cell interactions actually taking place in patients remains to be determined.
2.8. Concluding remarks
The tumor microenvironment plays a key role in supporting malignant cells. In B cell leukemia 
and lymphoma, the malignant B cells seem to have retained their ability to receive help from 
their physiological interaction partners, the T
h
 cells. Consistently, current research supports a 
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 contribution of T
h
 cells to the development and progression of various types of B cell malignancies. 
Effective anticancer therapies should include targeting the cells of the tumor microenviron-
ment. Thus, research efforts leading to the identification and characterization of malignant 
collaboration between T
h
 cells and malignant B cells may provide novel strategies for therapies 
aiming to target the tumor microenvironment.
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